Completed PHASE3 INTERVENTIONAL NCT00346450

Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation

Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface

Sponsor: International Stem Cell Forum

Conditions Chemical Injury Ocular Surface Disease Pterygium Stevens Johnson Syndrome

Interventions Cultivated conjunctival transplantation

Updated 5 times since 2017 Last updated: Jan 11, 2010 Started: Oct 31, 2001 Completion: Dec 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chemical Injury and Ocular Surface Disease, this trial is completed. The trial is conducted by International Stem Cell Forum and has accumulated 5 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

International Stem Cell Forum
National Medical Research Council (NMRC), Singapore
Singapore Eye Research Institute
Singapore National Eye Centre

Data source: Singapore National Eye Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore